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ABSTRACT
Alzheimer's Disease (AD) and Parkinson's Disease (PD) are both progressive
neurodegenerative disorders that affect millions of Americans and for which there are no cures.
AD can significantly impair the ability to think, remember, communicate, and carry out daily
activities, while PD can affect motor functions such as balance, coordination, and the ability to
speak. Intracellular protein aggregation is a hallmark of both diseases, with AD being
characterized by the build up of neurofibrillary tangles composed of misfolded tau protein and
PD being characterized by Lewy bodies composed of alpha-synuclein. Both normal tau and
alpha-synuclein can localize to the nucleus; however, their nuclear roles have not been fully
elucidated. These proteins bind and stabilize alternative DNA structures, which form most
readily at purine-pyrimidine repeats. The 1f promoter of the Nitric Oxide Synthase I (NOSI)
gene, which is misregulated in both AD and PD, contains one such repeat. This NOSI repeat is
polymorphic and has the sequence (TG)mTA(TG)n where m and n can vary from individual to
individual. Genotyping shows that shorter dinucleotide polymorphisms are associated with AD
and PD. Promoters with shorter repeats also have decreased transcriptional expression compared
to promoters with larger repeats. Because tau and alpha-synuclein can bind such repeats, we
hypothesize that tau and alpha-synuclein may modulate NOSI transcription through the
(TG)nTA(TG)m repeat. Reporter genes directed by the NOSI 1f promoter with and without the
(TG)nTA(TG)m repeat region were transfected into human neuroblastoma cells (SK-N-MC) and
human cervical cancer cells (HeLa) that express varying levels of tau and alpha-synuclein.
Promoters with the TG repeat directed approximately two-fold changes in reporter gene
expression, while promoters without the TG repeat caused no change in expression. These
findings suggest that tau and alpha-synuclein modulate NOSI expression through interaction with
a dinucleotide polymorphism associated with disease development. 	
  
	
  

5	
  

BACKGROUND
Both Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are progressive,
neurodegenerative disorders which account for millions of deaths each year (Centers for Disease
Control and Prevention, 2015). The severe and debilitating nature of AD and PD make it
imperative that we investigate the molecular mechanisms underlying neurodegeneration. AD and
PD are similar in that they are both characterized by protein misfolding which leads to protein
aggregation. Misfolded tau and alpha-synuclein accumulate in potentially pathogenic
intracellular neurofibrillary tangles in AD and PD, respectively (Vasudevaraju et al., 2012).
Understanding the normal function of tau and alpha-synuclein is critical in understanding the
pathology of these neurodegenerative diseases.
In neurons, tau, short for tubulin associated factor, functions to maintain microtubule
stability which is critical for cellular transport through axons (Duan et al., 2012).
Hyperphosphorylation causes tau to dissociate from microtubules, allowing the microtubules to
depolymerize. The free hyperphosphorylated tau is truncated and can then aggregate into
neurofibrillary tangles (Mania et al., 2015; Frost et al., 2014; Duan et al., 2012 & Lee et al.,
2001). It is unclear whether free truncated tau or the neurofibrillary tangles themselves are more
toxic to the cell. Some studies suggest that neurofibrillary tangles are toxic, while others suggest
that neurofibrillary tangles are a cellular protective mechanism against free truncated tau (Mania
et al., 2015).
Alpha-synuclein is a neuron-specific protein localized primarily in the nucleus and
presynaptic nerve terminals (Maroteaux et al., 1988). Its exact function in the cell is still
unknown; however, many studies suggest significant implications of α-synuclein in synaptic
transmission (Cabin et al., 2002). A missense mutation in the gene that encodes alpha-synuclein
(SNCA) was associated with familial cases of early-onset PD. The mutation in SNCA is one
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potential cause of Lewy Body formation and is thought to disrupt secondary protein structure
leading to self-aggregation of alpha-synuclein (Polymeropoulos et al., 1997). Alpha-synuclein
has since been studied in the contexts of PD pathogenesis, but the exact role of the protein in
neurodegeneration has yet to be elucidated.
Much research on AD and PD has focused on the roles of tau and alpha-synuclein in the
cytoplasm; however, focusing only on these tangles has failed to fully explain the mechanisms
behind neurodegeneration. Therefore, our study examines the role of tau and alpha synuclein in
the nucleus.	
  Unphosphorylated tau and alpha-synuclein localize to the nucleus. Although their
nuclear binding site has yet to be elucidated, several studies suggest they bind preferentially to
purine-pyrimidine repeats in the DNA (Sultan et al., 2011; Vasudevaraju et al., 2012 & Liu and
Gotz, 2013). Purine-pyrimidine repeats can often be found in promoter regions where
transcription of the gene produces negative supercoils, which can cause the DNA in the repeat
region to switch into alternative forms (Cox et al., 2012). Furthermore, one study showed that
the tau protein is capable of binding and stabilizing a CG oligonucleotide in the Z-DNA
conformation, while alpha-synuclein stabilizes the oligonucleotide in an altered B-DNA
conformation (Vasudevaraju et al., 2012). Circular dichroism studies have detected Z-DNA in
post-mortem AD brains, while DNA isolated from PD brains is far more likely to contain altered
B-DNA structures, which do not match any currently crystallized forms of DNA (Vasudevaraju
et al., 2012). Thus, tau may be responsible for changes in the DNA structure observed in AD, as
well as alpha-synuclein in PD.
Because these changes in DNA structure are occurring in promoter regions, they are
likely to affect transcription factor access to the DNA. Thus, tau and alpha-synuclein induction
or stabilization of alternate DNA structures could affect transcription of the genes with purine-
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pyrimidine repeats within their promoter regions (Vasudevaraju et al., 2012). The Nitric Oxide
Synthase I gene (NOSI), which is misregulated in both AD and PD, contains a purine-pyrimidine
repeat in its promoter region. Therefore, it is a good model to study the ability of tau and alphasynuclein to modulate gene expression at purine-pyrimidine repeats.
Many studies associate the misregulation of NOSI with neurodegenerative disorders
including AD and PD (Knott and Bossy-Wetzel, 2009 and Przedborski et al., 1996). The NOSI
enzyme produces secondary messenger nitric oxide (NO), which is crucial for the regulation of a
variety of body functions including controlling blood pressure, long-term memory, synapse
formation, pain regulation, muscle movement, glucose regulation, and urine formation (Toda and
Okamura, 2003; & Prast, 2001). The most direct link between NOSI and neurodegenerative
disease was discovered using the MPTP mouse model. Mice treated with MPTP develop PD-like
symptoms, while NOSI-deficient mice treated with MPTP do not develop PD symptoms
(Przedborski et al., 1996). These findings suggest that NOSI plays a role in MPTP-induced
neurotoxicity. NOSI transcription must be tightly regulated, as excess NO can have neurotoxic
effects, while low levels can have neuroprotective effects (Sultana et al., 2006). Thus,
transcriptional misregulation of NOSI likely contributes to the pathology of AD and PD, making
it important to examine the NOSI promoter.
Transcriptional regulation of NOSI is highly complex but has not been extensively
studied. The human NOSI gene, located on chromosome 12, is over 160 kb in length and consists
of 29 exons (Hall et al., 1994). Of these 29 exons, 12 first exons (1a-l) controlled by 12 separate
first promoters are alternatively spliced to exon 2, which contains the translation start site (Rife
et al., 2009). Expression of the different first exons is tissue specific with first exons 1d, 1f, and
1g predominating in the brain (Bros et al, 2006). This study focuses on the human 1f promoter,

	
  

8	
  

which contains a polymorphic purine-pyrimidine repeat, (TG)mTA(TG)n (Figure 2). Shorter
lengths of this purine-pyrimidine repeat correlate with a higher risk of both AD and PD
(Galimberti et al., 2008, Rife et al., 2009). Previous gene expression assays revealed that NOSI
constructs containing the polymorphic (TG)mTA(TG)n repeat change their expression in response
to tau knockdown as well as alpha-synuclein overexpression. These studies also showed that
longer repeats respond more than shorter repeats to changing levels of tau and alpha-synuclein,
indicating that changes in gene expression may be mediated through the (TG)mTA(TG)n repeat.

C.

Figure 1. Map of human NOSI gene and an example mRNA transcript. A) Schematic of the
12 first exons that are alternatively spliced to the protein coding exons 2-29. B) Example mRNA
transcript of exon 1f spliced to exon 2 with a marked translation start site in exon 2. C) Sequence
of NOSI 1f promoter region from GenBank reference numbers 1441-1655 containing the
polymorphic (TG)mTA(TG)n repeat. The repeat is shown in pink, and the TATA box is shown in
blue. Figure 1A and 1B were obtained from Logan Murphy.
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Hypothesis:
In summary, the tau protein creates neurofibrillary tangles in AD neurons, while alphasynuclein creates tangles in PD neurons. Studies have shown that both of these proteins can enter
the nucleus and bind preferentially to purine-pyrimidine repeats, a common site for altered DNA
structures found in AD and PD brains (Vasudevaraju et al. 2012). The NOSI gene, which is
known to be misregulated in both AD and PD, contains a polymorphic thymine-guanine repeat in
its 1f promoter. Because shorter repeats are more highly correlated with AD and PD and because
varying length repeats express differently in response to tau and alpha-synuclein, we hypothesize
that tau and alpha-synuclein are modulating the expression of NOSI through this
(TG)mTA(TG)n repeat.
To test our hypothesis, we created and tested three new NOSI promoter deletion
constructs and compared expression of their luciferase reporter gene to that of an already existing
full length NOSI 1f promoter under high and low tau and alpha-synuclein levels. The Full
Promoter construct contains a 54 bp (TG)mTA(TG)n repeat while the ΔTG construct includes the
entire promoter excluding only the (TG)mTA(TG)n (Figure 2). If tau or alpha-synuclein act
through the TG repeat, then we expect no change in expression in the ΔTG construct when tau or
alpha-synuclein levels are changed. We also made two 5' deletion constructs of the full promoter
– Δ5’ Region and Δ5’ Region & TG. The Δ5’ Region construct contains the entire
(TG)mTA(TG)n repeat with no upstream sequences and the Δ5’ Region &TG construct has no
repeat or upstream sequences (Figure 2). Expression assays with construct Δ5’ Region allow us
to either rule out or consider the upstream region of the NOSI promoter as a potential site of
regulation for tau and alpha-synuclein. Because this construct includes the
(TG)mTA(TG)n repeat, we expect Δ5’ Region to exhibit similar expression changes to the Full
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Promoter construct when tau and alpha-synuclein are differentially expressed. The Δ5’ Region &
TG construct will allows us to narrow down whether tau and alpha-synuclein could be regulating
transcription through only the region downstream of the (TG)mTA(TG)n repeat. We expect this
construct to exhibit no expression changes when tau is knocked-down or alpha-synuclein
overexpressed. However, if ΔTG or Δ5’ Region & TG change expression in response to
differential tau and alpha-synuclein expression, we will have to consider other regions of the
NOSI promoter as potential sites of regulation for these proteins.

1

1502

1567
(TG)14TA(TG)12

1834
FULL NOSI PROMOTER
Δ TG

(TG)14TA(TG)12

Δ 5’ REGION
Δ 5’ REGION & TG

Figure 2. Schematic of the human NOSI 1f promoter with modified clones used in this
study. The full NOSI promoter containing the (TG)14TA(TG)12 repeat was obtained from the
Young lab at Ohio State University. Light pink bars indicate the regions upstream of the
(TG)14TA(TG)12 repeat while dark pink bars indicate regions downstream of the (TG)14TA(TG)12
repeat. Red flags indicate GenBank Reference numbers where deletions were made. The ΔTG,
Δ5’ Region, and the Δ5’Region & TG constructs were cloned into a pGL3 luciferase reporter
gene for this study. 	
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METHODS:
Cloning:
PCR using the Full Promoter as a template was performed to obtain truncated NOSI
promoters for cloning into pGL3 luciferase vectors. Table 1 contains the primers designed to
amplify the targeted promoter regions. The ΔTG required three rounds of PCR to stitch
nucleotides 1-1504 to nucleotides 1567-1834 (Figure 3), while constructs Δ5’ Region and Δ5’
Region & TG required only one round of PCR (Figure 4).
ΔTG Reaction 1a
TGn

Fwd primer with KpnI site

ΔTG Rev primer
ACn

ΔTG Reaction 1b
TGn

ΔTG Fwd primer

Rev primer with BglII site
ACn

ΔTG Reaction 2

ΔTG Reaction 3
Rev primer with BglII site

Fwd primer with KpnI site

Figure 3. Schematic of PCR for the ΔTG construct. The pink lines represent the NOSI Full
Promoter, and the maroon lines represent the (TG)14TA(TG)12 repeat. Reaction 1 produces the
upstream and downstream region of the ΔTG construct that will be attached to remove the
(TG)14TA(TG)12 repeat. The light gray 5’ overhangs of theΔTG Fwd and ΔTG Rev primers
contain sequence from the other side of the repeat that is being removed; these overhangs also
contain regions that are complementary to each other and will bind as shown in ΔTG Reaction 2.
The forward and reverse primers containing a KpnI and BglII site, respectively, are utilized so
that ΔTG can be cloned into pGL3.
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TGn

Fwd primer Δ5’ Region
Fwd primer Δ5’ Region & TG
Rev primer with BglII site
ACn

Figure 4. Schematic of PCR for constructs Δ5’ Region and Δ5’ Region & TG. The pink lines
represent the NOSI Full Promoter, and the maroon lines represent the (TG)14TA(TG)12 repeat.
The forward primer for Δ5’ Region binds to the TG repeat, while the forward primer for Δ5’
Region & TG binds directly after the TG repeat. The reverse primer binds to the downstream
region of the Full Promoter, and the 5’ region of the reverse primer contains a hanging BglII
restriction site to allow for cloning into pGL3.
Table 1. Forward and reverse primer sequences used to clone various regions of the NOSI
promoter. ΔTG requires three reactions while Δ5’ Region and Δ5’ Region & TG require one.
KpnI sites are indicated in red, while BglII sites are indicated in blue. The dark grey forward
primers both contain the same sequence, and the light grey reverse primers contain the same
sequence.
Reaction/Construct
ΔTG Reaction 1a
ΔTG Reaction 1b
ΔTG Reaction 2
ΔTG Reaction 3
Δ5’ Region
Δ5’ Region & TG
Sequencing Primer 1
Sequencing Primer 2

Forward Primer Sequence (5’ to 3’)
Reverse Primer Sequence (5’ to 3’)
GGGGTACCAAGCTTGTGCTCCCAGAG
GAGGGTCTTTAACAGTAAAAGG
GTCATTTTCGTGATAGAAAAAAAA
CACTCCTCGATGAATCGCGTCTAGAAG
Nested PCR using complementary products from ΔTG 1a and ΔTG 1b
GGGGTACCAAGCTTGTGCTCCCAGAG
CACTCCTCGATGAATCGCGTCTAGAAG
CATTGTGTGTGTGTGTGTGTGTGTGTGTGT CACTCCTCGATGAATCGCGTCTAGAAG
TTTCCTGATAGAAAAAAAAAAATGG
CACTCCTCGATGAATCGCGTCTAGAAG
CTTTATGTTTTTGGCGTCTTCCA
CTAGCAAAATAGGCTGTCCC

Each polymerase chain reaction mixture contained 1X high fidelity PCR buffer, 0.2 mM
dNTP, 2 mM MgSO4, 0.2 µM forward primer, 0.2 µM reverse primer, 1.0 units platinum Taq
high fidelity DNA polymerase, and 200 ng plasmid or PCR product. All PCR reactions
containing primers were run at 94 °C for 2 minutes to denature, followed by 30 cycles of 94 °C
for 30 seconds, 50 °C for 30 seconds, and 68 °C for 1 minute, and then a final round of 68 °C for
10 minutes. Nested PCR reactions without primers used to clone No TG reaction 2 ran for only
15 cycles under the same conditions. Final PCR products were run on a 2% agarose gel, purified
with the Invitrogen PureLink Quick Gel Extraction & PCR Purification Combo kit, and inserted
into the pCR®2.1-TOPO® TA cloning plasmid vector according to the New England BioLabs
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(NEB) T4 DNA Ligase protocol (Figure 5). The ligated recombinants were transformed into
competent One Shot® E. coli cells and grown on ampicillin plates spread with 40 µL of 40
mg/mL X-Gal. Blue-White screening was used to select colonies that contain successfully
inserted PCR product. White colonies were cultured in LB broth, mini-prepped, digested with
EcoRI, and examined on a 1% agarose gel to determine if the correct size construct was present.
Vectors of the correct size and orientation were cut out of the cloning vector with BglII and
Acc65I, band isolated, purified using the Invitrogen PureLink Quick Gel Extraction & PCR
Purification Combo Kit, and inserted into pGL3 via sticky-end ligation according to the NEB T4
DNA Ligase protocol (Figure 5). Recombinant pGL3 vectors were transformed into competent
E. coli cells, mini-prepped, digested with Acc65I and BglII, and run on a 1% agarose gel to
ensure that the expected constructs were successfully inserted prior to sending them for
sequencing. All recombinant plasmids were sequenced at the Plant-Microbe Genomics Facility at
Ohio State University. Sequencing reactions were analyzed using NCBI Blast and the 4Peaks
chromatogram tool. Constructs with confirmed sequences were maxi prepped using the
Invitrogen PureLink HiPure Plasmid Filter Maxi Prep Kit and DNA concentrations were
calculated with Qubit Fluorometer.
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Figure 5. Cloning strategy for NOSI promoter constructs. PCR products with adenine
overhangs were inserted into the pCR®2.1-TOPO® vector and ligated to its thymine overhangs.
If correctly inserted, the PCR product will disrupt transcription of the lacZα gene, allowing for
Blue-White selection. Correctly ligated recombinants were digested with Acc651 and BglII, and
the NOSI promoters were ligated into the KpnI and BglII sites of the pGL3-Basic vector.
Cell Line Maintenance:
SK-N-MC cells were grown in Eagles Modified Minimal Medium (EMEM)
supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum, and 100 units /mL
penicillin/streptomycin. HeLa cells were grown in DMEM high glucose media with 2mM Lglutamine, 10% (v/v) fetal bovine serum, and 100 units/mL penicillin/streptomycin. SK-N-MC
cells were maintained at 37 ˚C with 5% CO2.
Transfection of Cell Lines:
1.25 x 106 SK-N-MC cells or 3.0 x 105 HeLa cells were seeded on 6-well plates 24 hours
prior to transfection. Reporter gene constructs with NOSI promoters were transfected into SK-NMC or HeLa cells, which endogenously express high levels of tau and low levels of alphasynuclein. To knock down tau expression, cells were transfected with iTau (Santa Cruz), an
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siRNA known to knock-down tau. An siRNA not known to knock down any human gene was
used as a control. Alpha-synuclein overexpression was achieved by transfecting a pSI-WTsyn
plasmid containing the alpha-synuclein gene donated from B.T. Hymen into cells. An empty pSIWTsyn plasmid was used as a control. All cells were cotransfected with Beta-galactosidase
plasmid, pNassβ, to normalize for transfection efficiency. The pGL3-Control vector with SV40
promoter and SV40 enhancer was utilized as a highly expressing positive control for luciferase
assays, and the pGL3-Basic plasmid with no inserted promoter was utilized as the negative
control. DNA quantities utilized in each transfection are found in Table 2. Cells with no
luciferase or beta-galactosidase transfected were utilized to normalize for background light
values in both assays.
Table 2. Quantities of DNA utilized in each transfection.
Construct
Reporter gene construct
Beta-galactosidase
iTau
siRNA
pSI-WTsyn
Control alpha-synuclein

Tau assay
5 µg
3 µg
-4
1.8 X 10 µMoles
-4
1.8 X 10 µMoles
---

Alpha-synuclein assay
3.5 µg
3.5 µg
--3.5 µg
3.5 µg

	
  

SK-N-MC transfections were done using both the Lipofectamine 2000 and Mirus Bio
Trans-IT X2 protocols, while HeLa transfections were performed only with Trans-It X2. Cells
were incubated for 24 hours after transfection at 37 C with 5% CO2. To harvest, transfected cells
were rinsed with sterile PBS and spun at 5000 g for 5 minutes. Dry pellets were stored at –80 C
for up to 1 week prior to assaying. These pellets were re-suspended in 300 µL 0.25 M Tris-HCl.
To lyse the cells, each tube was sonicated at amplitude 60 on ice for 7 pulses no more than 1
second long. Lysed cells were spun at 13000 g for 10 minutes at 4 C. The supernatant contained
the gene products of interest.
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Luciferase Assay:
Luciferase was used as a reporter gene to measure gene expression directed by our cloned
NOSI promoters. For each sample, a Berthold Detection Systems SIRIUS luminometer injected
100 µL of luciferin into a cuvette containing 350 µL of substrate and 40 µL of cell extract. The
proportions for the substrate include 0.5 volume of 50mM gly-gly pH 7.8, 0.25 volume
of10mg/mL ATP pH 6-8, 0.10 volume of 150 mM MgSO4, and 0.15 volume of H2O. The
luminometer reports luciferase activity in relative light units (RLU).
Protein Assay:
The protein assay was used to normalize for the number of cells in each sample. One
milliliter of room temperature Bio-Rad Protein Reagent Dye (1 part filtered dye to 4 parts water
stock) was added to a cuvette for each sample followed by either five microliters of protein
standards at 0.0, 0.125, 0.25, 0.5, 0.75, 1.0, 1.25, and 1.47 mg/mL or ten microliters of cell
extract. Absorbance was measured at 595 nm.
Beta-Galactosidase Assay:
Beta-galactosidase (Bgal) assays were used to normalize for transfection efficiency. Each
reaction contained 60 μL of cellular extract, 3 μL of 100X Mg solution (0.1 M MgCl2, 4.5 M
beta-mercaptoethanol), 66 μL of 1X ONPG (a 4 mg/mL solution of o-nitrophenyl-β-Dgalactopyranoside dissolved in 0.1 M sodium phosphate), and 151 of μL 0.1 M sodium
phosphate at pH 7.5 (41 mL 0.2 M Na2HPO4 * 2H2O, 9 mL 0.2 M NaH2PO4- * 2H2O, and 50 mL
H2O). Reactions were incubated at 37 °C for 60 minutes or until a faint yellow color developed.
Reactions were stopped with 500 μL of 1.0 M sodium bicarbonate and measured in a
spectrophotometer at 420 nm.
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Data Analysis:
Expression was recorded as mean relative light units (RLU) per unit of beta-galactosidase
(Bgal Unit) activity per minute ± standard deviation. Expression fold-changes were calculated
between high and low tau or alpha-synuclein, and two-tailed t-tests were performed to determine
significance which was assigned at p<0.05 in all tests.
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RESULTS
Cloning:
The ΔTG, Δ5’ Region, and Δ5’ Region & TG constructs were made to examine whether
the TGm(TA)TGn repeat in the NOSI 1f promoter may be a binding site for tau and alphasynuclein to regulate NOSI gene transcription. The constructs were first made from PCR on the
NOSI Full Promoter template and were cloned into the pCR®2.1-TOPO® cloning vector.
Insertion into the cloning vector was verified as correct by digesting plasmids with EcoRI and
observing the expected 1810 bp fragment of ΔTG, 364 bp fragment of Δ5’ Region, and 299 bp
fragment of Δ5’ Region & TG. Correct plasmids were cut with BglII and Acc65I, inserted into
the pGL3 reporter gene vector.
When the ΔTG construct was inserted into pGL3, we observed the expected 4818 bp
fragment from pGL3 and a smaller 1795 bp ΔTG promoter fragment upon digestion with BglII
and Acc651 (Figure 6). The Δ5’ Region construct was obtained in the pCR®2.1-TOPO® cloning
vector from previous lab work by Kristen Grathwald (Rife et al., 2009). Upon digestion of Δ5’
Region in pGL3 with Acc651 and BglII, we observed the expected 4818 bp fragment and the 349
bp fragment containing the Δ5’ Region promoter (Figure 6). Finally, the expected 4818 bp and
284 bp fragments of the Δ5’ Region & TG construct were observed upon digestion with Acc651
and BglII (Figure 6). The completed plasmids are 6582 bp, 5167 bp, and 5102 bp for ΔTG, Δ5’
Region, and Δ5’ Region & TG, respectively.
Once restriction enzyme digests confirmed the intended plasmid design, the constructs
were sequenced by the Ohio State Plant Microbe Genome Facility. The resulting sequences were
blasted against our expected sequence for each plasmid, and we determined that each plasmid
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contained the correct sequence with no mutations. Sequencing output data can be found in
Appendix 1.
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Figure 6. Gel evidence of insertion of NOSI promoter constructs ΔTG, Δ5’ Region, and Δ5’
Region & TG into reporter gene vector pGL3. All pGL3 vectors containing the correct NOSI
promoter were digested with BglII and Acc65I overnight at 37 °C. Lane 1 contains the pGL3
vector and the ΔTG promoter. Lane 2 contains a 500 bp molecular weight ladder, whose band
sizes are marked on the left side of the gel in base pairs. Lane 3 contains pGL3 vector and the
Δ5’ Region promoter, and lane 4 contains pGL3 and the Δ5’ Region & TG promoter. Lane 5
contains a 100 bp molecular weight ladder whose band sizes in base pairs are marked on the
right.

	
  

20	
  

Effect of tau knock-down on NOSI promoter activity in SK-N-MC cells:
Constructs Full Promoter, Δ5’ Region, and Δ5’ Region & TG were transfected into SKN-MC cells, along with either iTau or control siRNA and luciferase expression assays were
performed to examine whether tau is mediating expression changes through the (TG)mTA(TG)n
repeat. Following tau knockdown, Full Promoter directed 8365.5 ± 540.1 RLU/Bgal Unit while
this construct expressed 4535.8 ± 292.4 RLU/Bgal Unit at high tau levels (Figure 7). Therefore,
tau knockdown induced a 1.84-fold increase in expression (p = 0.014) of a reporter gene directed
by the Full Promoter construct. The Δ5’ Region construct exhibited a 1.63-fold increase in
expression (p = 0.002) with RLU/Bgal Unit values of 5461.7 ± 387.3 and 3360.5 ± 2.349 for low
and high tau levels, respectively (Figure 7). Construct Δ5’ Region & TG had a 1.01-fold change
in expression (p = 0.918), with low tau conditions yielding 2991.2 ± 133.8 RLU/Bgal Unit and
high tau conditions yielding 3009.0 ± 306.1 RLU/Bgal Unit. Two additional assays of tau
knockdown with the Full Promoter yielded a 1.40-fold (p = 0.057) and a 1.82-fold (p = 0.0003)
increase in expression. The assay yielding a 1.40-fold change was calculated using RLU values
from the tau knockdown and no siRNA conditions. Subsequent experiments with Δ5’ Region
construct yielded 1.50-fold (p = 0.050) and 1.68-fold (p = 0.002) increases in expression, while
the Δ5’ Region & TG construct yielded 1.05-fold (p = 0.984) and 1.02-fold (p = 0.263) increases
in expression, showing virtually no change when tau was knocked down.
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Figure 7. The effect of tau knock-down on NOSI promoter activity in SK-N-MC cells. NOSI
1f promoter reporter gene constructs were transfected into SK-N-MC cells with betagalactosidase and either iTau or a control siRNA not known to knock down any human gene.
The results of the luciferase assays were presented as relative light units (RLU) over units of
beta-galactosidase activity per minute. Data represent the average values for three repeated trials.
Error bars represent one standard deviation, and a * indicates constructs that were significantly
different from controls in a t-test (p < 0.05).
Effect of alpha-synuclein overexpression on NOSI promoter activity in SK-N-MC cells:
The Full Promoter, construct Δ5’ Region, and construct Δ5’ Region & TG were
transfected into SK-N-MC cells along with either an alpha-synuclein overexpression vector or a
control vector, and luciferase expression assays were performed to examine whether alphasynuclein is mediating expression changes through the (TG)mTA(TG)n repeat. The Full Promoter
had expression values of 4264.0 ± 352.5 and 2054.9 ± 243.0 RLU/Bgal Unit for conditions of
low and high alpha-synuclein, respectively, demonstrating a 2.07-fold decrease in expression (p
= 0.022) upon alpha-synuclein overexpression (Figure 8). The Full Promoter displayed a 2.18fold (p = 0.048) and a 2.08-fold (p = 0.012) decrease in expression upon two subsequent trials of
alpha-synuclein overexpression. The Δ5’ Region promoter directed expression levels of 3037.0 ±
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185.1 RLU/Bgal Unit under low alpha-synuclein conditions and 1437.4 ± 329.6 RLU/Bgal Unit
under high alpha-synuclein conditions, resulting in a 2.11-fold decrease in expression (p = 0.033)
(Figure 8). On the other hand, no changes in expression were observed in construct Δ5’ Region
& TG. At low alpha-synuclein levels, the Δ5’ Region & TG construct directed 2839.1 ± 202.0
RLU/Bgal Unit, and at high alpha-synuclein levels, the Δ5’ Region & TG promoter directed
2798.1 ± 236.7 RLU/Bgal Unit, accounting for a 1.01-fold change in expression (p = 0.892)
(Figure 8). The Δ5’ Region & TG promoter also directed 0.99-fold change in expression in two
subsequent experiments (p = 0.880).
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Figure 8. The effect of alpha-synuclein overexpression on NOSI promoter activity in SK-NMC cells. NOSI 1f promoter constructs were cloned in front of luciferase in the pGL3 reporter
gene vector (Promega). NOSI reporter gene constructs into SK-N-MC cells with betagalactosidase and either an alpha-synuclein overexpression vector (pSI-WTsyn) or a control
vector. The results of luciferase assays are presented as relative light units (RLU) over units of
beta-galactosidase activity per minute. Data represent the average values for three repeated trials.
Error bars represent one standard deviation, and an * indicates constructs that were significantly
different from controls in a t-test (p < 0.05).
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Effect of alpha-synuclein overexpression on NOSI promoter activity in HeLa cells:
To examine the role of alpha-synuclein in the regulation of the NOSI promoter in a
different cell line, we optimized the protocol for HeLa cells and performed a single trial using.
We determined that the following conditions were optimal for experiments with HeLa cells:
§
§
§
§
§

Seed cells at a concentration of 3.0x105 cells per well, rather than 1.25x106 cells per well
Add TransIT-X2 reagent in a 2:1 TransIT-X2:ng DNA ratio in HeLa rather than a 3:1 ratio
Thoroughly mix the transfection reagent, DNA, and media prior to the incubation period by
pipetting the entire volume up and down
Incubate transfection reagent, DNA, and media for 15 minutes at room temperature before
adding to cells
Utilize 40 µL cell extract for luciferase assays and 60 µL cell extract for beta-galactosidase
assays
We transfected only the Full Promoter construct and construct Δ5’ Region & TG into

HeLa cells along with either an alpha-synuclein overexpression vector or a control vector, and
the constructs expressed at higher levels than in SK-N-MC. The Full Promoter construct
displayed a 2.23-fold increase in expression (p<0.05) when alpha-synuclein was overexpressed
(Figure 9), whereas alpha-synuclein overexpression was associated with a decrease in expression
in SK-N-MC cells (Figure 8). Additionally, expression driven by the Δ5’ Region & TG promoter
construct increased 2.81-fold (p<0.05), despite the absence of the (TG)mTA(TG)n repeat (Figure
9).
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Figure 9. The effect of alpha-synuclein overexpression on NOSI promoter activity in HeLa
cells. NOSI 1f promoter constructs were transfected into HeLa cells with beta-galactosidase and
either an alpha-synuclein overexpression vector (pSI-WTsyn) or a control vector. The results of
luciferase assays are presented as relative light units (RLU) over units of beta-galactosidase
activity per minute. Data represent the average values for three repeated trials. Error bars
represent one standard deviation, and an * indicates constructs that were significantly different
from controls in a T-test (p < 0.05).
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DISCUSSION
To examine whether tau and alpha-synuclein are modulating transcription of the NOSI
gene at a polymorphic (TG)mTA(TG)n repeat, we measured gene expression driven by variations
of the NOSI promoter. A large portion of our project involved cloning these promoter constructs
into the pGL3 luciferase reporter gene vector. The sequencing output matched our expected
sequences for constructs ΔTG, Δ5’ Region, and Δ5’Region & TG, so we can reasonably trust
that all expression data from those constructs did not occur as a result of cloning mutations. The
ΔTG construct was not finished in time to put into any assays, but it will be used in the next
experiments. When tau was knocked down in SK-N-MC cells, the Full Promoter and construct
Δ5’ Region, which both contain the (TG)mTA(TG)n repeat, displayed a significant increase in
expression. However, construct Δ5’ Region & TG, which excludes the repeat, displayed no
significant change in expression in response to tau knockdown. Thus, tau appears to only affect
gene expression when the (TG)mTA(TG)n repeat is present, which is consistent with our
predictions.
Furthermore, when alpha-synuclein was overexpressed in SK-N-MC cells, both the Full
Promoter and Δ5’ Region displayed approximately 2-fold decreases in expression. However, the
Δ5’ Region & TG construct that excludes the repeat did not exhibit a significant change in
expression. Overexpressed alpha-synuclein had no effect on expression when the (TG)mTA(TG)n
repeat was deleted, suggesting that the (TG)mTA(TG)n repeat may also be necessary for alphasynuclein mediated transcriptional changes in SK-N-MC. However, expression levels were low
for these constructs in SK-N-MC, so it is questionable whether excess alpha-synuclein could
have further suppressed transcription in the Δ5’ Region & TG construct. Therefore, we tested the
constructs in HeLa cells, which are known to robustly express our NOSI promoter constructs.
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Although HeLa cells are a non-neuronal cell line, they express multiple neuronal genes including
alpha-synuclein, and are frequently used to study neurological conditions such as AD and PD
(Culvenor et al., 1995; & Liu et al., 2012).
As we hoped, the Full Promoter and Δ5’ Region & TG constructs expressed at higher
levels in HeLa than in SK-N-MC. The Full Promoter exhibited a 2.23-fold increase in
expression in HeLa but a 2.08-fold decrease in expression in SK-N-MC when alpha-synuclein
was overexpressed. Additionally, the Δ5’ Region & TG construct showed a significant 2.81-fold
increase in expression in HeLa cells, but showed no change in expression in SK-N-MC cells
when alpha-synuclein was overexpressed. While it appears that alpha-synuclein is modulating
NOSI expression in HeLa cells, the (TG)nTA(TG)m repeat may not be required. The differences
in expression between SK-N-MC and HeLa experiments are likely due to the presence of
different transcription factors in the cell lines. Alpha-synuclein could be interacting with other
proteins and transcription factors, and subsequently regulating transcription through a different
region in the promoter. The data from HeLa experiments will need to be repeated to confirm
these results because difficulties with cell growth may have affected the results.
HeLa cells should be incubated with CO2 levels between 5% and 10%; however, our
incubator consistently displays CO2 levels greater than 10% for unknown reasons. Elevated
levels of CO2 can induce oxidative stress (McKenna, 2009), and studies have shown that this
stress increases nuclear levels of alpha-synuclein (Siddiqui et al., 2012). Therefore, it is possible
that this stress on our cells caused alpha-synuclein to localize to the nucleus, regardless of
whether or not cells were transfected with alpha-synuclein. If alpha-synuclein is binding to DNA
in the low alpha-synuclein condition, it would mimic the results of alpha-synuclein
overexpression. Despite the need for further optimization, our preliminary data is promising in
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that it indicates that alpha-synuclein overexpression does change the way our promoter
constructs express.
Studies have implicated overexpressed alpha-synuclein in causing differential expression
of genes other than NOSI, one of which is called PGC1-alpha. PGC1-alpha is a transcriptional
co-activator involved in the activation of several genes implicated in mitochondrial biogenesis
and cellular respiration (Siddiqui et al., 2012). Misexpression of PGC1-alpha has been reported
in the brains of sporadic PD patients (Mallajosyala et al., 2009). Siddiqui et al. (2012) identified
a CCCCTTCC consensus sequence for alpha-synuclein binding and observed decreased PGC1alpha promoter activity upon alpha-synuclein overexpression. These studies implicate alphasynuclein binding in PGC1-alpha expression changes; however, a mechanism has yet to be
established. Interestingly, the PGC1-alpha promoter construct purchased from Addgene contains
a 50 bp TG repeat. Currently, our lab is working to corroborate the work of Siddiqui et al. and
show whether this TG repeat is needed for alpha-synuclein induced changes in PGC1-alpha
transcription. Our experiment in HeLa cells revealed a 2-fold increase in PGC1-alpha expression
with overexpressed alpha-synuclein, which is opposite the trend observed by Siddiqui et al and
in our NOSI experiments with SK-N-MC. The Siddiqui et al. studies were performed in PC12
cells derived from a pheochromocytoma of the rat adrenal medulla, a tissue that has neuroblastic
origins. Therefore, overexpressed alpha-synuclein appears to decrease expression of promoter
constructs in neuronal cell lines, while increasing expression in HeLa cells. Additional studies
with this construct in HeLa and SK-N-MC cells may reveal whether alpha-synuclein promotes or
inhibits PGC1-alpha expression in these cells and whether these expression changes are
mediated through a TG repeat.
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Although we have not tested it, the ΔTG construct will provide better information on the
impact of the polymorphic (TG)mTA(TG)n repeat on NOSI promoter expression because it
contains the entire promoter sequence, including enhancers and repressors that would normally
be necessary for NOSI gene transcription. Although the (TG)mTA(TG)n repeat has been
correlated with AD and PD, other TG repeats in the NOSI promoter could be affecting gene
expression even in the absence of the large repeat. For example, there are two smaller TG repeats
further upstream in the NOSI 1f promoter: a 16 bp TG repeat starting at bp 848 and a
(TG)5TA(TG)2 repeat beginning at bp 866 (Figure 10). According to the literature, tau is able to
bind to purine-pyrimidine repeats as short as 13 bp (Mania et al., 2016). Construct ΔTG may still
be affected by tau and alpha-synuclein due to these smaller TG repeats. The additional upstream
TG repeats could explain small differences in fold-change between the Full Promoter and Δ5’
Region.
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Figure 10. NOSI 1f promoter sequence displaying smaller upstream TG repeats. The dark
grey highlighted region shows the 16 bp TG repeat beginning at bp 848 as well as the
TG5(TA)TG2 repeat beginning at bp 866. The light grey highlighted region shows the
polymorphic repeat that is known to be correlated with AD and PD.
Although it appears that tau and alpha-synuclein are modulating gene expression in the
NOSI promoter, regulation may not be through direct binding. For a more definitive answer to
whether tau and alpha-synuclein are binding to the (TG)nTA(TG)m repeat, future studies will
utilize ChIP-PCR. This procedure crosslinks proteins to DNA and utilizes antibodies to pull
down either tau or alpha-synuclein with bound DNA. Subsequent qPCR analysis using primers
specific to the region of the NOSI gene containing the (TG)nTA(TG)m repeat would determine
whether tau or alpha-synuclein are modulating transcription through direct binding to the repeat.
ChIP-sequencing performed on a cohort of PD patients demonstrated that alpha-synuclein can
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bind to the promoter region of genes such as NEDD4, CDC42, and SLC4A5, and that it can
increase promoter activity of SLC4A5 (Pinho, et al, 2014). We examined the aforementioned
genes on the UCSC Genome Browser, but we were unable to find any TG repeats longer than a
few base-pairs within 2,000 base-pairs of the transcriptional start sites. The longest purinepyrimidine repeat we found was an 11 bp TA repeat in NEDD4, suggesting that alpha-synuclein
may be altering gene expression through motifs other than a purine-pyrimidine repeat. Another
ChIP-sequencing study also identified NEDD4 and CDC42 as major peaks on a list of 238 target
genes for alpha-synuclein binding in PD (Martins et al., 2011). We aligned the NOSI promoter
sequence with NEDD4, CDC42, and pGC1-alpha to investigate other potential regulatory
sequences, and the results can be found in Table 3. We may wish to explore these sequences in
the future.
Table 3. Potential regulatory sequences identified based on alignment of NOSI 1f promoter
with other promoters known to bind alpha-synuclein. The sequence outputs aligned with
100% identity in NCBI BLAST®.
Alignment

Potential Regulatory Sequences
5’-CTCCAGGCCTCC-3’

NOSI to NEDD4

5’-CCTGGGGCTGG-3’
5’-CGGGCTCCTGG-3’

NOSI to CDC42

5’-GCCTCTTCTCT-3’
5’-AGAAAGGAAGGGAAG-3’

NOSI to pGC1-alpha

5’-AGGCTCCCAGAAA-3’
5’-AAGAAAGGAAGG-3’
5’-GAAAAGATCAAA-3’

Although the mechanism by which tau modulates expression of NOSI is still unclear, our
study indicates that it may be acting at the (TG)mTA(TG)n repeat. Many studies have
demonstrated that tau can impact gene expression, and there are a variety of suggestions
regarding its DNA-binding preferences and sequence specificity (Mania et al., 2016). Thus, it is
important to test tau knockdown in HeLa cells. One study indicated that tau bound and bent the
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DNA through electrostatic interactions at AT-rich regions in the minor groove, preferentially at
sequences of 13 bp or longer (Wei et al., 2008). Another study indicated that tau bound to GC
rich oligonucleotides in addition to AT-rich regions (Camero et al., 2014). Thus, tau’s binding
preferences may be based on hydrophobicity or general structure of the backbone as opposed to
specific sequences (Camero et al., 2014). Because the (TG)mTA(TG)n repeat is capable of
forming alternative DNA structures, we believe that the polymorphic repeat is worth pursuing in
future investigations.
The cellular mechanisms involved in neurodegeneration are complex, and animal models
are critical to better understanding and treating the associated diseases. Animal models of AD
and PD have focused heavily on the role of intracellular neuronal plaques and tangles; however,
these rodent models have provided us with limited success in developing new clinical treatments
and in demonstrating how neurofibrillary tangles contribute to disease pathology (Howell, 2015).
In addition to our work discussed in this paper, we also generated a promoter construct with an
extra short (TG)4TA(TG)2 repeat for future use in the lab (Appendix 2). This construct was
modeled after the very short (TG)mTA(TG)n repeat found in the NOSI promoter of mice and rats.
If this construct responds to alpha-synuclein and tau less significantly than the human Full
Promoter constructs, it may indicate that shorter purine-pyrimidine repeats in rodents make them
less susceptible to pathological changes in gene expression. These discrepancies in gene
expression could explain the shortcomings of current rodent models.
Currently, there are no cures for either Alzheimer’s Disease or Parkinson’s Disease, and
there are limited treatments to inhibit their progression. Protein modulation of NOSI gene
expression may only be a small piece of the complex cellular machinery that goes awry in
devastating neurodegenerative diseases. However, understanding this mechanism may point to a
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novel role for the proteins that have been implicated in these diseases. Furthermore, this study
may further expand our knowledge about the ways in which purine-pyrimidine repeats as well as
altered B-DNA structures affect gene expression in a wide variety of cellular processes.
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APPENDICES
APPENDIX 1. Sequencing output from Ohio State University Plant-Microbe Genomics
Facility for cloned NOSI promoter constructs in pGL3.
Table a. Sequencing results for ΔTG construct. The final plasmid contains the entire pGL3
vector, shown in red, a portion of the pCR2.1 cloning vector in blue, and the PCR product in
green.
ΔTG Construct Reaction 1 (GL Primer 2) 	
  
NNNNNNNNNNNNNNNNNGATGCCAGCTTACTTAGATCGCAGATCTGCGCTAAGTAGCTCCTCACCCAGCGGCTGGAAACGCGGCATAAATATGTAG
GGACTGAGCCGTGAGCTCAGCGAGGATCGTGAGGGGGAATTTATTTCTTAATGTCCCTCCTTTATCCTATCATCACTGAAACGAATTAGCAGTGACGT
CCAACCCGACTGGTTTATGGGTGTGGGGAGGGAGACGTCGCAACCCTCATTAAAAGAGCCGCTCTGGGCTCCAAAGCATACATCTTTTATATAACCTA
ATTTCCATTTTTTTTTTTNTATCAGGAAAATGACACACACACACACACACACATACACACACACACACACACACACACACACAATGACAATTTCTGGG
AGCCTGGATAGGGCTGAATGTAGTAGCCACGCAGGGCAGGGCAGGTCTATTTGGGCAGAGAAGGCCCCATGGGAGGCAGGGATGGTTATTTCTGCCT
CTACATCANTGTTGGGANNGCATTCCTTAATGGGACAGTGGAACACACNNCCTCCCAGGCTGGGCAGTGCTGGGAGCCCCTCCCANGAGCCCGCANA
GGTTGCAGCCTGGGTTCTGGCCTTGGCTCTCGGGTGGACAGACNGANAAAAGCANCCTGTTCNNAAATGTTGCCTGGTTCTGGTCTTTTCTGGAGCCA
CACTCAGGCCTGGCATCTGGGGAGAGTGANNATGGANGGCACATGTTTCNTCTGTGGCCTGNGAGCCCNACNNTGTGGAGANGCCAANGNCTGGGC
TGGAGGANGAGAAGACACNGANAACNCANCTTCCCTTCNTTNTCTTAGGGGCCCTAACATATGGGTAANCATATAAACCCNACTNAAAATCTGTCTT
TTCTTGGGCAGATTNCNAAGGATTTNNCNNCTCCCNTTGCTGTTGCTGCTGCTCNCNNNNCTTGGGAAAACGGGGAAAANCATGGAANANANGACAC
NANNN 	
  

ΔTG Construct Reaction 2 (RV Primer 3) 	
  
NNNNNNNNNNNNNNNNNANNTTTCTCTATCGATAGGTACCAAGCTTGTGCTCCCAGAGAGGAAGTGCCCCTACTCTGAGCTTCTTTTGGCCTTGACCC
ACACATAGGCAGACGTGGACTCTGTTTTGAGCAGGTGAACCGCCAGCCCAGTGGAAGAGCAGCTTCCCTTCCCCTAGCTTCCTGATTTTCCCCAGTTG
CCATGGTAATTGAGGGAGCAGTGTTCTGAGAATGACACCACTGAAACCCAGCGCTCAACTTTGAAATGGTTCGGGCAAGGGACGCTGGACCCAAAAC
AGGAGGGGACCAGACTGCAAGGACTCAGCTCCAGCCTCAATTTTCTGGGACCCACCCCCCATCCAGCCTGTATGCTGGATTATTCTCATCATCATCAA
AATCACCATTATTGTTGGCAACTGTTTCCTGAGCATTTACTATATGTCTAGCACCATGTCAAGGGCTTCACCAGCATCATCTCATTGTGTATATCCTCA
CGACATCCCCAGGCCCATCCATGGCTCAGGAAACAGGCTCTGAAACTTGCCCTTGTGGCAGCCAGGAAGTGGCAGAGCCCTGGGGCTGGTGGCATTT
CTCCAGGCCTCCTTCCAGCATGTGGAAGACAGCATAGACCTCCAGGCACCCTCGTCAGCTTATTCTTTATTCCTTCCTCCCCTCCTCATCCCCCACACC
CTTCTTCCTGCCCCCAAAGTCACACACCCCCTCCCCTGCTGGATGTGCAAGACGATCTGAAAAGCATTTATTAGTGACAAAGGGGGTGGTGGTTTTCC
TCTTTGCCTCTTCTCTGCGCAACTCGAANCCTGANTGGGTTTGCTCCGCTTGGCAAGGCTGGGGANGANGAAAAGATCAAATCACCCNNAGCCAGGT
GCCAAGTGTGTGTGTGTGTGTGTTTGTGTGTNNNNAGNGCGCNTGTGCNCNTGNNNNNNNGTGTGTCNCTCNTTCCTTGATTTTNCCCCGTTTTCNCA
GNNTNTGTGAGCNNCNGCANNGNNACNGGANANNNAAATNCNTTGNNNCTGCNNNNANNNNNNTTTGANNCNNNNNNNNGNTTCCGTNNGTTNNN
CCCTANANNGNAGNNNCNNNNNNNTNTNNNNCTTCCNCNNNNNNNNNNNNNNNNNNNCTNGNNGGNTCAGNNNNNATNANNNNNNNNNNNCNNN
NTNNNNNANTNNNTCTGANTNNNNNNCNNNNNNNNNNNNN 	
  

ΔTG Construct Reaction 3 (Middle Primer) 	
  
NNNNNNNNNNNNCNNGTTCTGGTCTTTTCTGGAGCCNCACTCAGGCCTGGCATCTGGGGAGAGTGAAGGATGGAGGGCACATGTTCATCTGTGGCCT
GGGAGCCCCACAGGTGTGGAGAGGCCAAGGTCTGGGCTGGAGGAGGGAAGACACAGAGAACGCAGCTTCCCTTCCTTTCTTAGGGGCCCTAACATAT
GGGTAACCATATAAACCCGACTCAAAATCTGTCTTTTCCTGGGCAGATTGCAAAGGATTTTGCATCTCCCCGTTGCTGTTGCTGCTGCTCACACAGTCT
TGGGAAAACGGGGGAAAATCAAGGAAAGAGAGGACACACACACGCGCACGCGCACACGCGCACATACACACACACAAACACACACACACACACAC
TTGGCACCTGGCTCTGGGTGATTTGATCTTTTCCTCCTCCCCAGCCTTGCCAAGCGGAGCAAACCCACTCAGGCTTCNAGTTGCGCAGAGAAGAGGCA
AAGAGGAAAACCACCACCCCCTTTGTCACTAATAAATGCTTTTCAGATCGTCTTGCACATCCAGCAGGGGAGGGGGTGTGTGACTTTGGGGGCAGGA
AGAANGGTGTGGGGGATGAGGAGGGGAGGAAGGAATAAAGAATAAGCTGACGAGGGTGCCTGGAGGTCTATGCTGTCTTCNACATGCTGGAANGA
GGCCTGGAGAAATGCCACCAGCCCCNNGGCTCTGCCACTTCNTGNCTGCCACAAGGGCNAGTTTNNNAGCCTGTTTCCTGAGCCATGGATGGGCCTG
GGGGATGTCNTGAGNAT 	
  

Confirmed ΔTG Promoter Sequence: 	
  
CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTG
TGCTGGAATTCGGCTTGGGGTACCAAGCTTGTGCTCCCAGAGAGGAAGTGCCCCTACTCTGAGCTTCTTTTGGCCTTGACCCACACATAGGCAGACGT
GGACTCTGTTTTGAGCAGGTGAACCGCCAGCCCAGTGGAAGAGCAGCTTCCCTTCCCCTAGCTTCCTGATTTTCCCCAGTTGCCATGGTAATTGAGGG
AGCAGTGTTCTGAGAATGACACCACTGAAACCCAGCGCTCAACTTTGAAATGGTTCGGGCAAGGGACGCTGGACCCAAAACAGGAGGGGACCAGAC
TGCAAGGACTCAGCTCCAGCCTCAATTTTCTGGGACCCACCCCCCATCCAGCCTGTATGCTGGATTATTCTCATCATCATCAAAATCACCATTATTGTT
GGCAACTGTTTCCTGAGCATTTACTATATGTCTAGCACCATGTCAAGGGCTTCACCAGCATCATCTCATTGTGTATATCCTCACGACATCCCCAGGCCC
ATCCATGGCTCAGGAAACAGGCTCTGAAACTTGCCCTTGTGGCAGCCAGGAAGTGGCAGAGCCCTGGGGCTGGTGGCATTTCTCCAGGCCTCCTTCCA
GCATGTGGAAGACAGCATAGACCTCCAGGCACCCTCGTCAGCTTATTCTTTATTCCTTCCTCCCCTCCTCATCCCCCACACCCTTCTTCCTGCCCCCAA
AGTCACACACCCCCTCCCCTGCTGGATGTGCAAGACGATCTGAAAAGCATTTATTAGTGACAAAGGGGGTGGTGGTTTTCCTCTTTGCCTCTTCTCTGC
GCAACTCGAAGCCTGAGTGGGTTTGCTCCGCTTGGCAAGGCTGGGGAGGAGGAAAAGATCAAATCACCCAGAGCCAGGTGCCAAGTGTGTGTGTGTG
TGTGTTTGTGTGTGTGTATGTGCGCGTGTGCGCGTGCGCGTGTGTGTGTCCTCTCTTTCCTTGATTTTCCCCCGTTTTCCCAAGACTGTGTGAGCAGCAG
CAACAGCAACGGGGAGATGCAAAATCCTTTGCAATCTGCCCAGGAAAAGACAGATTTTGAGTCGGGTTTATATGGTTACCCATATGTTAGGGCCCCT
AAGAAAGGAAGGGAAGCTGCGTTCTCTGTGTCTTCCCTCCTCCAGCCCAGACCTTGGCCTCTCCACACCTGTGGGGCTCCCAGGCCACAGATGAACAT
GTGCCCTCCATCCTTCACTCTCCCCAGATGCCAGGCCTGAGTGTGGCTCCAGAAAAGACCAGAACCAGGCAACATTTCCTGAACAGGCTGCTTTTCTC
CGTCTGTCCACCCGAGAGCCAAGGCCAGAACCCAGGCTGCAACCTCTGCGGGCTCCTGGGAGGGGCTCCCAGCACTGCCCAGCCTGGGAGGCTGTGT
GTTCCACTGTCCCATTAAGGAATGCTATCCCAACACTGATGTAGAGGCAGAAATAACCATCCCTGCCTCCCATGGGGCCTTCTCTGCCCAAATAGACC
TGCCCTGCCCTGCGTGGCTACTACATTCAGCCCTATCCAGGCTCCCAGAAATTGTCATTTTCCTGATAGAAAAAAAAAAATGGAAATTAGGTTATATA
AAAGATGTATGCTTTGGAGCCCAGAGCGGCTCTTTTAATGAGGGTTGCGACGTCTCCCTCCCCACACCCATAAACCAGTCGGGTTGGACGTCACTGCT
AATTCGTTTCAGTGATGATAGGATAAAGGAGGGACATTAAGAAATAAATTCCCCCTCACGACCCTCGCTGAGCTCACGGCTCAGTCCCTACATATTTA
TGCCGCGTTTCCAGCCGCGCTACTTAGCGCAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCCAAAA
ACATAAAG 	
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Table b. Sequencing results for the Δ5’ Region construct. The final plasmid contains the entire
pGL3 vector, shown in red, a portion of the pCR2.1 cloning vector in blue, and the PCR product
in green. 	
  
Δ5’ Region Construct Reaction 1 (GL Primer 2) 	
  
NNNNNNNNNNNNCGGNTGCCAGCTTACTTAGATCGCAGATCTGCGCTAAGTAGCTCCTCACCCAGCGGCTGGAAACGCGGCATA
AATATGTAGGGACTGAGCCGTGAGCTCAGCGAGGGTCGTGAGGGGGAATTTATTTCTTAATGTCCCTCCTTTATCCTATCATCACT
GAAACGAATTAGCAGTGACGTCCAACCCGACTGGTTTATGGGTGTGGGGAGGGAGACGTCGCAACCCTCATTAAAAGAGCCGCT
CTGGGCTCCAAAGCATACATCTTTTATATAACCTAATTTCCATTTTTTTTTTTCTATCAGGAAACACACACACACACACACACACAC
ATACACACACACACACACACACACACACACAATGAAGCCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGT
ACCTATCGATAGAGAAATGTTCTGGCACCTGCACTTGCACTGGGGACAGCCTATTTTGCTAGTTTGTTTTGTTTCGTTTTGTTTTGA
TGGAGAGCGTATGTTAGTACTATCGATTCACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATATTTTATTGCGGCCGC
TCCAAGTACCTCCCGTACCTTAATATTACTTACTTATCANGGTAGCTTGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCC
CTTCCCAACAGTTGCGCAGCCTGAATGGCGAANGGCAAATTGTAAGCGTTAATATTTTGNNAAAATTCGCGTTAAATTTTNGTTAA
ATCAGCTCATTTTTTAACCNATAGGCCGAAATCGGCAAAATCCNTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTG
TTCCAGTTTGGAACAAGAGTCCACTNTTAAAGAACGTGGANTCCAANGTCAANGGCGAAAAACCGTNTATCAGGGCGATGGNCC
CACTACGTGAACCATCACCCTANTCAAGTTTTTTGGGGTCGANGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGGAGCCCC
CGAATTTANAGNTTGACGGGGAAAGCNCGGCNAACNTGGNNGAAAGNNAGGGNNNAAAGCNAANGGANCGGGNNNTTAGGGC
GCTTGGCAANTGTANCGGTNANCGCNNNCGCNNACTCNNNNNNNNNNNNNNCNNNTTANNNCNCNNNTACNGGGGCGNNGNNN
NGNGGCNNNTTTTTNNGGGAAANTNNGNGCNNNGGNANCCCNNNNNNNGNNNNNNNNNNNNNAAANNNNNTTNNAAANNNNN
NNNNCNCTCNNNNGANANNANNNNNNNNNAANAANNNNCTTNCNANTAANNTNNNNNNNNAANANNNNNNNANNNNNNNNNN
NNNTNNNCNNNNNNNNCCCNNNNNTNNNNNNNTNNNGNCGNNNNNTNTNNNNGCNCNNNNNNNNNNNNNT 	
  

Δ5’ Region Construct Reaction 2 (RV Primer 3): 	
  
NNNNNNNNNNNANTTTCTCTATCGATAGGTACCGAGCTCGGATCCNCTAGTAACGGCCGCCAGTGTGCTGGAATTCGGCTTCATT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTTTCCTGATAGAAAAAAAAAAATGGAAATTAGG
TTATATAAAAGATGTATGCTTTGGAGCCCAGAGCGGCTCTTTTAATGAGGGTTGCGACGTCTCCCTCCCCACACCCATAAACCAGT
CGGGTTGGACGTCACTGCTAATTCGTTTCAGTGATGATAGGATAAAGGAGGGACATTAAGAAATAAATNCCNCCTCACGACCCTC
GCTGAGCTCACGGCTCAGTCCCNACATATTTATGCCGCGNTTCCAGCCGNTGGGTGAGGAGCTACTTAGCGCAGATCTGCGATCT
AAGTAAGCTTGGCATTCCGGTACTGTTGGNAAAGNCACNATGGAAGACGCCAAANACATNAAGAAAGGCCCGGCGCCATTCTAT
CCGCTGGAAGATGGAACCGCTGGAGAGCNACTGCNTAAGGCTATGAANAGATACGCCCTGGTTCCTGGAACAATTGCTTTTACAG
ATGCACATATCGAGGTGGACATCACTTACGCTGANTACTTCNAAATGTCCGTTCGGTTGGCAGAAGCNNTGAAACGATATGGGCT
GAATACAAATCACANAATCGTCGTATGCANNTGAAAACTCTCTTCANTTCTTTTATGCCGGTGTTGGGCGCGTTTATTTATCGGAG
TTGNAGTTGCGCCCGCGAACGACATTTATAATGAANGTGAATTGCTCAACCAGTANGNGCNNNTCGCAGCCTACCGNGGTGTTCG
TTTTCNNAAAGGGGTTGCNAAAATTTTTGAACGTTGCNAAAAANNCTCCCCANTCNTCCNNAA 	
  

Confirmed Δ5’ Region Construct sequence: 	
  
CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCGAGCTCGGATCCACTAGTAA
CGGCCGCCAGTGTGCTGGAATTCGGCTTCATTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTT
TCCTGATAGAAAAAAAAAAATGGAAATTAGGTTATATAAAAGATGTATGCTTTGGAGCCCAGAGCGGCTCTTTTAATGAGGGTTG
CGACGTCTCCCTCCCCACACCCATAAACCAGTCGGGTTGGACGTCACTGCTAATTCGTTTCAGTGATGATAGGATAAAGGAGGGA
CATTAAGAAATAAATTCCCCCTCACGACCCTCGCTGAGCTCACGGCTCAGTCCCTACATATTTATGCCGCGTTTCCAGCCGCTGGG
TGAGGAGCTACTTAGCGCAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCCAAA
AACATAAAG 	
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Table c. Sequencing results for the Δ5’ Region & TG construct. The final plasmid contains the
entire pGL3 vector, shown in red, a portion of the pCR2.1 cloning vector in blue, and the PCR
product in green. 	
  
Δ5’ Region & TG Construct Reaction 1 (GL Primer 2) 	
  
NNNNNNNNNNNNNNCGGNNGCCAGCTTACTTAGATCGCAGATCTGCGCTAAGTAGCTCCTCACCCAGCGGCTGGAAACGCGGCA
TAAATATGTAGGGACTGAGCCGTGAGCTCAGCGAGGGTCGTGAGGGGGAATTTATTTCTTAATGTCCCTCCTTTATCCTATCATCA
CTGAAACGAATTAGCAGTGACGTCCAACCCGACTGGTTTATGGGTGTGGGGAGGGAGACGTCGCAACCCTCATTAAAAGAGCCG
CTCTGGGCTCCAAAGCATACATCTTTTATATAACCTAATTTCCATTTTTTTTTTTCTATCAGGAAAAAGCCGAATTCCAGCACACTG
GCGGCCGTTACTAGTGGATCCGAGCTCGGTACCTATCGATAGAGAAATGTTCTGGCACCTGCACTTGCACTGGGGACAGCCTATTT
TGCTAGTTTGTTTTGTTTCGTTTTGTTTTGATGGAGAGCGTATGTTAGTACTATCGATTCACACAAAAAACCAACACACAGATGTA
ATGAAAATAAAGATATTTTATTGCGGCCGCTCCAAGTACCTCCCGTACCTTAATATTACTTACTTATCATGGTAGCTTGGGCTGGC
GTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCAAATTGTAAGCGTTAATAT
TTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATANGCCGAAATCGGCAAAATCCCTTATAAATCAA
AAGAATAGACCGAGATAGGGTTGAGTGTTGNTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGNACTCCAACGTCAAAG
GGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGNTTTTTTGGGGTCGAGGTGCCGTAAAG
CACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCNAGAAGGAAGGNAAGA
AAGCGAAGGAGCGNGCGCTAGGGCGCTGGCAGTGTAGNGGNCACGCTGCGNGTAATCACCACACCCGCCGCGCNTAANGCNCCG
CTACAGGNNNNNNNGGTGNNNNTTTTCGGGGAAATNNGCGCGAACCCCNNTTNGTTATTTTNNNAANNACANTNNNTNNNNNTC
CGCTCNNGNANACNANACCNNGANNAATGCNTCATANNNTGAAAAANNNNNNTNTNNNNNATNNNNNNNNCNNNNNNNNNNTC
NNNTTTNNNGCATTNCNNCNGNTTTGCNNNCCNNNNNNNGGNNNAGNNAAGAAGNCNNNNNCNNNNNNNNNCANNNNGTNG 	
  

Δ5’ Region & TG Construct Reaction 2 (RV Primer 3) 	
  
NNNNNNNNNNNANNTTTCTCTATCGATAGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCGGCTTTTT
CCTGATAGAAAAAAAAAAATGGAAATTAGGTTATATAAAAGATGTATGCTTTGGAGCCCAGAGCGGCTCTTTTAATGAGGGTTGC
GACGTCTCCCTCCCCACACCCATAAACCAGTCGGGTTGGACGTCACTGCTAATTCGTTTCAGTGATGATAGGATAAAGGAGGGAC
ATTAAGAAATAAATTCCCCCTCACGACCCTCGCTGAGCTCACGGCTCAGTCCCTACATATTTATGCCGCGTTTCCAGCCGCTGGGT
GAGGAGCTACTTAGCGCAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCCAAAA
ACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTGGAAGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACG
CCCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGGACATCACTTACGCTGAGTACTTCGAAATGTCCGTTCGG
TTGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGC
CGGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATTGCTCAACAGTATGGG
CATTTCGCAGCCTACCGTGGTGTTCGTTTCCAAAAAGGGGTTGCAAAAAATTTTGAACGTGCAAAAAAAGCTCCCAATCATCCAA
AAAATTATTATCATGGATTCTAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTCGTCACATCTCATCTACCTCCCGGTTT
TAATGAATACGATTTTGTGCCANANTCCTTCGATAGGGACAAGACAATTGCACTGATCATGAACTCCTCTGGATCTACTGGNCTGC
CTAAAGNNGTCGCTCTGCCTCATAGAANTGCCTGCGNGAGATTCTCGCATGNCANANATCCTANTTTGGCNNTNNAATCNTTCCN
GNATACTGCGATTTTNANNNTNNNNCCATTNCATCACGGTTTNGNNNNTTACTACACTCGNANATTTGATATGTGGANTTNNNNN
CGNNNNANNNNNAGATTGANANNANCTGTTTTNNNAGNNCNNNNNNTNNAGATCAANNNNNCNNCTNNNNNNNCNANNNTNNN
NNNNTNNNNNAGNNNNNNNNNTNNNNAANNNNATTNNNNNNNNNNNNNNNNNNNNNNNNNGNNNNNCCNNNNTN 	
  

Δ5’ Region & TG Construct Promoter Sequence 	
  
CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCGAGCTCGGATCCACTAGTAA
CGGCCGCCAGTGTGCTGGAATTCGGCTTTTTCCTGATAGAAAAAAAAAAATGGAAATTAGGTTATATAAAAGATGTATGCTTTGG
AGCCCAGAGCGGCTCTTTTAATGAGGGTTGCGACGTCTCCCTCCCCACACCCATAAACCAGTCGGGTTGGACGTCACTGCTAATTC
GTTTCAGTGATGATAGGATAAAGGAGGGACATTAAGAAATAAATTCCCCCTCACGACCCTCGCTGAGCTCACGGCTCAGTCCCTA
CATATTTATGCCGCGTTTCCAGCCGCTGGGTGAGGAGCTACTTAGCGCAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTG
TTGGTAAAGCCACCATGGAAGACGCCAAAAACATAAAG 	
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APPENDIX 2: Cloning strategy for the rodent construct containing (TG)4TA(TG)2
polymorphism.
We have already conducted cloning and sequencing for the construct containing a
(TG)4TA(TG)2 repeat, modeled after the extra short polymorphism in the rodent NOSI promoter.
We refer to this construct as the Rodent construct. The Rodent construct required three rounds
of PCR, similar to the strategy for ΔTG (Figure 3). Reaction 1a uses forward primer
GGGGTACCAAGCTTGTGCTCCCAGAG and reverse primer
GAAACACATACACACACAATGACAATTTCTGG. Reaction 1b uses forward primer
CATTGTGTGTGTATGTGTTTCCTGATAGAAA and reverse
primer CACTCCTCGATGAATCGCGTCTAGAAG. Reaction 3 uses forward primer
GGGGTACCAAGCTTGTGCTCCCAGAG, and reverse primer GGAAAATGACA
ATTTCTGGGAG. The Rodent construct was cloned into pGL3 and sequenced. The final
expected plasmid was 6679 bp. However, we found a discrepancy between sequencing reaction 2
and our expected Rodent sequence (Table d). The highlighted region of Table d shows only
two cytosines (C) rather than the expected three C's. The discrepancy does not appear in the
other two sequencing reactions because they do not cover that region. The chromatogram
corroborates the error, but it is possible that the deletion resulted from a sequencing error
rather than a cloning error. An additional sequencing reaction is needed to confirm this
result. Future studies must be done to examine whether Rodent contains a true mutation
and how this promoter directs expression in cells with and without tau and alpha-synuclein.
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Table d. Sequencing results for the Rodent construct containing (TG)4TA(TG)2 polymorphism. The final
plasmid contains the entire pGL3 vector, shown in red, a portion of the pCR2.1 cloning vector in blue,
and the PCR product in green. The highlighted region contains a discrepancy between our expected
sequence and sequencing reaction 2. 	
  
Rodent Construct Reaction 1 (GL Primer 2) 	
  
NNNNNNNNNNNNNNACCNGATGCCAGCTTACTTAGATNNNNNATCTGCGCTAAGTAGCTCCTCACCCAGCGGCTGGAAACGCGGCATAAATATGTAGGGACTGA
GCCGTGAGCTCAGCGAGGGTCGTGAGGGGGAATTTATTTCTTAATGTCCCTCCTTTATCCTATCATCACTGAAACGAATTAGCAGTGACGTCCAACCCGACTGGTT
TATGGGTGTGGGGAGGGAGACGTCGCAACCCTCATTAAAAGAGCCGCTCTGGGCTCCAAAGCATACATCTTTTATATAACCTAATTTCCATTTTTTTTTTTCTATC
AGGAAACACATACACACACAATGACAATTTCTGGGAGCCTGGATAGGGCTGAATGTAGTAGCCACGCAGGGCAGGGCAGGTCTATTTGGGCAGAGAAGGCCCCA
TGGGAGGCAGGGATGGTTATTTCTGCCTCTACATCAGTGTTGGGATAGCATTCCTTAATGGGACAGTGGAACACACAGCCTCCCAGGCTGGGCAGTGCTGGGAGC
CCCTCCCAGGAGCCCGCAGAGGTTGCAGCCTGGGTTCTGGCCTTGGCTCTCGGGTGGACAGACGGAGAAAAGCAGCCTGTTCAGGAAATGTTGCCTGGTTCTGGT
CTTTTCTGGAGCCACACTCAGGCCTGGCATCTGGGGAGAGTGAAGGATGGAGGGCACATGTTCATCTGTGGCCTGGGAGCCCCACAGGTGTGGAGAGGCCAAGG
TCTGGGCTGGAGGAGGGAAGACACAGAGAACGCANCTTCCCTTCCTTTCTTANGGGCCCTAACATATGGGTAACCATATAAACCCNACTCAAAATCTGTCTTTTC
CTGGGCAGATTGCAAAGGATTTTGCATCTCCCCGTTGCTGTTGCTGCTGCTCNCACAGTCTTGGAAAACGGGGAAAATCNAGGAAAGANAGGACACACATACNC
GCACGCGCACACNNNCNCATACNNNCNCNCNNNNNNNNNNNNNNNNNNNTTGGCNCCTNGNNCNNGNNANTTGNTCTTTTTCCTNNNCCNNNCTNGCCAGCGG
NNNAANNCNNNCNGNNTNNNNTNNNNNANAANNGNTANANNAACACNNNNNNTGTNCNNNNATAANNCTTTNNNTCNNNTGNCANNCNNNGNNNNGNNNNNN
ANNTNNNNNGAANNNNNNNNNNNNNNNNNNNGATNNNNNNNNNNTANNNNNNNNCNNNNNN 	
  

Rodent Construct Reaction 2 (RV Primer 3) 	
  
NNNNNNNNGNNCNNANNTTTCTCTATCGATAGGTACCAAGCTTGTGCTCCAGAGAGGAAGTGCCCCTACTCTGAGCTTCTTTTGGCCTTGACCCACACATAGGCA
GACGTGGACTCTGTTTTGAGCAGGTGAACCGCCAGCCCAGTGGAAGAGCAGCTTCCCTTCCCCTAGCTTCCTGATTTTCCCCAGTTGCCATGGTAATTGGGGGAGC
AGTGTTCTGAGAATGACACCACTGAAACCCAGCGCTCAACTTTGAAATGGTTCGGGCAAGGGACGCTGGACCCAAAACAGGAGGGGACCAGACTGCAAGGACTC
AGCTCCAGCCTCAATTTTCTGGGACCCACCCCCCATCCAGCCTGTATGCTGGATTATTCTCATCATCATCAAAATCACCATTATTGTTGGCAACTGTTTCCTGAGCA
TTTACTATATGTCTAGCACCATGTCAAGGGCTTCACCAGCATCATCTCATTGTGTATATCCTCACGACATCCCCAGGCCCATCCATGGCTCAGGAAACAGGCTCTG
AAACTTGCCCTTGTGGCAGCCAGGAAGTGGCAGAGCCCTGGGGCTGGTGGCATTTCTCCAGGCCTCCTTCCAGCATGTGGAAGACAGCATAGACCTCCAGGCACC
CTCGTCAGCTTATTCTTTATTCCTTCCTCCCCTCCTCATCCCCCACACCCTTCTTCCTGCCCCCAAAGTCACACACCCCCTCCCCTGCTGGATGTGCAAGACGATCTG
AAAAGCATTTATTAGTGACAAAGGGGGTGGTGGTTTTCCTCTTTGCCTCTTCTCTGCGCAACTCGAANCCTGAGTGGGTTTGCTCCGCTTGGCAAGGCTGGGGAGG
ANGAAAAGATCAAATCACCCANAGCCAGGTGCCAAGTGTGTGTGTGTGTGTGTTTGTGTGTGTGTATGTGCGCGTGTGCNCNTGNNNNTATGTGTGTCCTCTCTTT
CCNTGANTTTCCCCNNTTTCCCAANNCTNNNNNNANCNGCANCNNCNGCNNNGGGNANANNCAAANTCCTTTNCANCTNNCCAGNAAANANNATTTTNNNNNG
GTTTNNNTGNNTNCCNTATGTTAGGNCNCTANNANNNANNNNCTNNNNTNTCNGNNNNNNNTCNCTCNNNNNNACNNNNNNNNNCNANNNNNNGNNTCNGTCN
NNNNANNNNNCNNCNTNNNNNNNNNNNAANNCANNNNNNNAGNNNNGNNNNNN 	
  

Rodent Construct Reaction 3 (Middle Primer) 	
  
NNNNNNNNNNNNTNCNNGTTCTGGTCTTTTCTGGAGCCNCACTCAGGCCTGGCATCTGGGGAGAGTGAAGGATGGAGGGCACATGTTCATCTGTGGCCTGGGAG
CCCCACAGGTGTGGAGAGGCCAAGGTCTGGGCTGGAGGAGGGAAGACACAGAGAACGCAGCTTCCCTTCCTTTCTTAGGGGCCCTAACATATGGGTAACCATAT
AAACCCGACTCAAAATCTGTCTTTTCCTGGGCAGATTGCAAAGGATTTTGCATCTCCCCGTTGCTGTTGCTGCTGCTCACACAGTCTTGGGAAAACGGGGGAAAAT
CAAGGAAAGAGAGGACACACATACGCGCACGCGCACACGCGCACATACACACACACAAACACACACACACACACACTTGGCACCTGGCTCTGGGTGATTTGATC
TTTTCCTCCTCCCCAGCCTTGCCAAGCGGAGCAAACCCACTCAGGCTTCGAGTTGCGCAGAGAAGAGGCAAAGAGGAAAACCACCACCCCCTTTGTCACTAATAA
ATGCTTTTCAGATCGTCTTGCACATCCAGCAGGGGAGGGGGTGTGTGACTTTGGGGGCAGGAAGAAGGGTGTGGGGGATGAGGAGGGGAGGAAGGAATAAAGA
ATAAGCTGACGAGGGTGCCTGGAGGTCTATGCTGTCTTCCACATGCTGGAAGGAGGCCTGGAGAAATGCCACCAGCCCCAGGGCTCTGCCACTTCCTGGCTGCCA
CAAGGGCAAGTTTCAGANCCTGTTTCCTGAGCCATGGATGGGCCTGGGGATGTCGTGAGGATATACACAATGAGATGATGCTGGTGAAGCCCTTGACATGGTGCT
ANACATATAGTAAATGCTCAGGAAACAGTTGCCAACAATAATGGTGATTTTGATGATGATGAGAATAATCCANCATACAGGCTGGATGGGGGGTGGGTCCCANA
AAATTGANCTGGNNCTGANTCCNTGCNNNCNNGTCCCTCCTGTTTTGGGNNCAGCGTCCCNTGCCNAACNATTTCNANTTGAGCGCNGGGTTTCAGTGGTGNNNT
NNNNGANNCTNCTCCCNNNNCATGGCACTGGGGAAANCNGANCNNGGNNNNCNNNTNTCNCTGGNTGGCNNNNNNNGCTNNAANNNNNNNNNNNNNNNNNNN
NNNNANNNNNNNNNNANNNNNNNNNTNTGNNNANCNNNNNNN 	
  

Confirmed full promoter sequence for Rodent Construct: 	
  
CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGATAGGTACCGAGCTCGGATCCACTAGTAA
CGGCCGCCAGTGTGCTGGAATTCGGCTTGGGGTACCAAGCTTGTGCTCCCAGAGAGGAAGTGCCCCTACTCTGAGCTTCTTTTGGC
CTTGACCCACACATAGGCAGACGTGGACTCTGTTTTGAGCAGGTGAACCGCCAGCCCAGTGGAAGAGCAGCTTCCCTTCCCCTAG
CTTCCTGATTTTCCCCAGTTGCCATGGTAATTGAGGGAGCAGTGTTCTGAGAATGACACCACTGAAACCCAGCGCTCAACTTTGAA
ATGGTTCGGGCAAGGGACGCTGGACCCAAAACAGGAGGGGACCAGACTGCAAGGACTCAGCTCCAGCCTCAATTTTCTGGGACC
CACCCCCCATCCAGCCTGTATGCTGGATTATTCTCATCATCATCAAAATCACCATTATTGTTGGCAACTGTTTCCTGAGCATTTACT
ATATGTCTAGCACCATGTCAAGGGCTTCACCAGCATCATCTCATTGTGTATATCCTCACGACATCCCCAGGCCCATCCATGGCTCA
GGAAACAGGCTCTGAAACTTGCCCTTGTGGCAGCCAGGAAGTGGCAGAGCCCTGGGGCTGGTGGCATTTCTCCAGGCCTCCTTCC
AGCATGTGGAAGACAGCATAGACCTCCAGGCACCCTCGTCAGCTTATTCTTTATTCCTTCCTCCCCTCCTCATCCCCCACACCCTTC
TTCCTGCCCCCAAAGTCACACACCCCCTCCCCTGCTGGATGTGCAAGACGATCTGAAAAGCATTTATTAGTGACAAAGGGGGTGG
TGGTTTTCCTCTTTGCCTCTTCTCTGCGCAACTCGAAGCCTGAGTGGGTTTGCTCCGCTTGGCAAGGCTGGGGAGGAGGAAAAGAT
CAAATCACCCAGAGCCAGGTGCCAAGTGTGTGTGTGTGTGTGTTTGTGTGTGTGTATGTGCGCGTGTGCCGTGCGCGTGTGTGTGT
CCTCTCTTTCCTTGATTTTCCCCCGTTTTCCCAAGACTGTGTGAGCAGCAGCAACAGCAACGGGGAGATGCAAAATCCTTTGCAAT
CTGCCCAGGAAAAGACAGATTTTGAGTCGGGTTTATATGGTTACCCATATGTTAGGGCCCCTAAGAAAGGAAGGGAAGCTGCGTT
CTCTGTGTCTTCCCTCCTCCAGCCCAGACCTTGGCCTCTCCACACCTGTGGGGCTCCCAGGCCACAGATGAACATGTGCCCTCCAT
CCTTCACTCTCCCCAGATGCCAGGCCTGAGTGTGGCTCCAGAAAAGACCAGAACCAGGCAACATTTCCTGAACAGGCTGCTTTTCT
CCGTCTGTCCACCCGAGAGCCAAGGCCAGAACCCAGGCTGCAACCTCTGCGGGCTCCTGGGAGGGGCTCCCAGCACTGCCCAGCC
TGGGAGGCTGTGTGTTCCACTGTCCCATTAAGGAATGCTATCCCAACACTGATGTAGAGGCAGAAATAACCATCCCTGCCTCCCAT
GGGGCCTTCTCTGCCCAAATAGACCTGCCCTGCCCTGCGTGGCTACTACATTCAGCCCTATCCAGGCTCCCAGAAATTGTCATTGT
GTGTGTATGTGTTTCCTGATAGAAAAAAAAAAATGGAAATTAGGTTATATAAAAGATGTATGCTTTGGAGCCCAGAGCGGCTCTT
TTAATGAGGGTTGCGACGTCTCCCTCCCCACACCCATAAACCAGTCGGGTTGGACGTCACTGCTAATTCGTTTCAGTGATGATAGG
ATAAAGGAGGGACATTAAGAAATAAATTCCCCCTCACGACCCTCGCTGAGCTCACGGCTCAGTCCCTACATATTTATGCCGCGTTT
CCAGCCGCGCTACTTAGCGCAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGAAGACGCCA
AAAACATAAAG 	
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